An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL

DOI Web Site 被引用文献58件
  • Guohua Pan
    G. Pan and V. M. Dixit, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
  • Jian Ni
    G. Pan and V. M. Dixit, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
  • Ying-Fei Wei
    G. Pan and V. M. Dixit, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
  • Guo-liang Yu
    G. Pan and V. M. Dixit, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
  • Reiner Gentz
    G. Pan and V. M. Dixit, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
  • Vishva M. Dixit
    G. Pan and V. M. Dixit, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.

抄録

<jats:p>TRAIL, also called Apo2L, is a cytotoxic protein that induces apoptosis of many transformed cell lines but not of normal tissues, even though its death domain–containing receptor, DR4, is expressed on both cell types. An antagonist decoy receptor (designated as TRID for TRAIL receptor without an intracellular domain) that may explain the resistant phenotype of normal tissues was identified. TRID is a distinct gene product with an extracellular TRAIL-binding domain and a transmembrane domain but no intracellular signaling domain. TRID transcripts were detected in many normal human tissues but not in most cancer cell lines examined. Ectopic expression of TRID protected mammalian cells from TRAIL-induced apoptosis, which is consistent with a protective role. Another death domain–containing receptor for TRAIL (designated as death receptor–5), which preferentially engaged a FLICE (caspase-8)–related death protease, was also identified.</jats:p>

収録刊行物

  • Science

    Science 277 (5327), 815-818, 1997-08-08

    American Association for the Advancement of Science (AAAS)

被引用文献 (58)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ